On January 11, 2017, Faruqi & Faruqi, LLP filed a federal antitrust class action case against brand and generic manufacturers of ADHD drug, Intuniv. The complaint alleges that the companies, Shire and Actavis, violated the antitrust laws by entering into an anticompetitive agreement that delayed generic competition for Intuniv. Under the agreement, Shire effectively paid Actavis tens of millions of dollars to delay launching a generic version of Intuniv. As a result, purchasers of Intuniv were forced to pay higher prices for the drug. The case was filed in the United States District Court for the District of Massachusetts and is captioned as follows: Rochester Drug Co-Operative Inc. v. Shire LLC et al., Case No. 1:17-cv-10050.